Literature DB >> 33840162

Correlation between BAL CXCR3 chemokines and lung allograft histopathologies: A multicenter study.

Michael Y Shino1, Ning Li1, Jamie L Todd2, Megan L Neely3, Jerry Kirchner4, Heather Kopetskie5, Michelle L Sever5, Courtney W Frankel2, Laurie D Snyder2, Elizabeth N Pavlisko6, Tereza Martinu7, Lianne G Singer7, Wayne Tsuang8, Marie Budev8, Pali D Shah9, John M Reynolds2, Nikki Williams10, Mark A Robien10, Scott M Palmer2, Stephen Sam Weigt1, John A Belperio1.   

Abstract

The histopathologic diagnosis of acute allograft injury is prognostically important in lung transplantation with evidence demonstrating a strong and consistent association between acute rejection (AR), acute lung injury (ALI), and the subsequent development of chronic lung allograft dysfunction (CLAD). The pathogenesis of these allograft injuries, however, remains poorly understood. CXCL9 and CXCL10 are CXC chemokines induced by interferon-γ and act as potent chemoattractants of mononuclear cells. We hypothesized that these chemokines are involved in the mononuclear cell recruitment associated with AR and ALI. We further hypothesized that the increased activity of these chemokines could be quantified as increased levels in the bronchoalveolar lavage fluid. In this prospective multicenter study, we evaluate the incidence of histopathologic allograft injury development during the first-year post-transplant and measure bronchoalveolar CXCL9 and CXCL10 levels at the time of the biopsy. In multivariable models, CXCL9 levels were 1.7-fold and 2.1-fold higher during AR and ALI compared with "normal" biopsies without histopathology. Similarly, CXCL10 levels were 1.6-fold and 2.2-fold higher during these histopathologies, respectively. These findings support the association of CXCL9 and CXCL10 with episodes of AR and ALI and provide potential insight into the pathogenesis of these deleterious events.
© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  cytokines/cytokine receptors; immunobiology; lung disease: immune/inflammatory; lung failure/injury; lung transplantation/pulmonology; rejection: acute; translational research/science

Mesh:

Substances:

Year:  2021        PMID: 33840162      PMCID: PMC8502500          DOI: 10.1111/ajt.16601

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   9.369


  25 in total

1.  Revisiting the pathologic finding of diffuse alveolar damage after lung transplantation.

Authors:  Masaaki Sato; David M Hwang; Kaori Ohmori-Matsuda; Cecilia Chaparro; Thomas K Waddell; Lianne G Singer; Michael A Hutcheon; Shaf Keshavjee
Journal:  J Heart Lung Transplant       Date:  2012-02-11       Impact factor: 10.247

Review 2.  Urinary incontinence in older adults.

Authors:  Camille P Vaughan; Patricia S Goode; Kathryn L Burgio; Alayne D Markland
Journal:  Mt Sinai J Med       Date:  2011 Jul-Aug

Review 3.  Risk factors for bronchiolitis obliterans: a systematic review of recent publications.

Authors:  Linda D Sharples; Keith McNeil; Susan Stewart; John Wallwork
Journal:  J Heart Lung Transplant       Date:  2002-02       Impact factor: 10.247

4.  Interstitial inflammatory lesions of the pulmonary allograft: a retrospective analysis of 2697 transbronchial biopsies.

Authors:  Christopher M Burton; Martin Iversen; Jørn Carlsen; Claus B Andersen
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

5.  Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis.

Authors:  Peter M Hopkins; Christina L Aboyoun; Prashant N Chhajed; Monique A Malouf; Marshall L Plit; Stephen P Rainer; Allan R Glanville
Journal:  Am J Respir Crit Care Med       Date:  2004-08-05       Impact factor: 21.405

6.  Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome.

Authors:  John A Belperio; Michael P Keane; Marie D Burdick; Joseph P Lynch; Ying Ying Xue; Kewang Li; David J Ross; Robert M Strieter
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

7.  Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection.

Authors:  Susan Stewart; Michael C Fishbein; Gregory I Snell; Gerald J Berry; Annette Boehler; Margaret M Burke; Alan Glanville; F Kate Gould; Cynthia Magro; Charles C Marboe; Keith D McNeil; Elaine F Reed; Nancy L Reinsmoen; John P Scott; Sean M Studer; Henry D Tazelaar; John L Wallwork; Glen Westall; Martin R Zamora; Adriana Zeevi; Samuel A Yousem
Journal:  J Heart Lung Transplant       Date:  2007-12       Impact factor: 10.247

8.  CXCR3 ligands are associated with the continuum of diffuse alveolar damage to chronic lung allograft dysfunction.

Authors:  Michael Y Shino; S Samuel Weigt; Ning Li; Vyacheslav Palchevskiy; Ariss Derhovanessian; Rajan Saggar; David M Sayah; Aric L Gregson; Michael C Fishbein; Abbas Ardehali; David J Ross; Joseph P Lynch; Robert M Elashoff; John A Belperio
Journal:  Am J Respir Crit Care Med       Date:  2013-11-01       Impact factor: 21.405

9.  The Prognostic Importance of Bronchoalveolar Lavage Fluid CXCL9 During Minimal Acute Rejection on the Risk of Chronic Lung Allograft Dysfunction.

Authors:  M Y Shino; S S Weigt; N Li; A Derhovanessian; D M Sayah; R Saggar; R H Huynh; A L Gregson; A Ardehali; D J Ross; J P Lynch; R M Elashoff; J A Belperio
Journal:  Am J Transplant       Date:  2017-08-02       Impact factor: 9.369

10.  The prognostic importance of CXCR3 chemokine during organizing pneumonia on the risk of chronic lung allograft dysfunction after lung transplantation.

Authors:  Michael Y Shino; S Samuel Weigt; Ning Li; Vyacheslav Palchevskiy; Ariss Derhovanessian; Rajan Saggar; David M Sayah; Richard H Huynh; Aric L Gregson; Michael C Fishbein; Abbas Ardehali; David J Ross; Joseph P Lynch; Robert M Elashoff; John A Belperio
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.752

View more
  1 in total

1.  Plasma CXCL9 and CXCL10 at allograft injury predict chronic lung allograft dysfunction.

Authors:  Michael Y Shino; Jamie L Todd; Megan L Neely; Jerry Kirchner; Courtney W Frankel; Laurie D Snyder; Elizabeth N Pavlisko; Gregory A Fishbein; Joanna M Schaenman; Kristen Mason; Karen Kesler; Tereza Martinu; Lianne G Singer; Wayne Tsuang; Marie Budev; Pali D Shah; John M Reynolds; Nikki Williams; Mark A Robien; Scott M Palmer; S Sam Weigt; John A Belperio
Journal:  Am J Transplant       Date:  2022-06-15       Impact factor: 9.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.